Biden Administration Pause On Pending Trump-Era Rules Stalls FDA Cannabinoids Guidance Progress

Among four FDA regulatory items withdrawn from OMB review is “Cannabidiol Enforcement Policy; Draft Guidance for Industry,” which the agency submitted in July 2020.

The already long and winding road to FDA allowing lawful use of cannabinoids in non-drug products has become longer and more winding.

Waiting for the US Food and Drug Administration to publish a draft guidance on cannabidiol enforcement? The wait grows longer with the withdrawal of the document along with other pending FDA regulatory items from the White House review process.

More from Cannabis/CBD

Senate Hemp Regulation Bill’s Broad Prohibition On Synthetics In Supplements Has Industry Attention

 

Provision in Wyden and Merkley’s “Cannabinoid Safety and Regulation Act” referencing FDA authority outside hemp-derived ingredients could provide agency with needed authority to force from the market products labeled as supplements but containing drugs or eliminate the use of many safe ingredients in supplements.

Senate Hemp Regulation Bill Offers Option To House’s Blanket Limit On Levels Of All THCs

 

Democrats Wyden and Merkley author Cannabinoid Safety and Regulation Act to limit sales to consumers 21 and older and authorize FDA to order recalls and impose bans on cannabis products with dangerous chemicals or additives. It also would establish regulatory structure for using cannabinoids found naturally in hemp and allowing “semi-synthetic” ingredients while prohibiting artificial or fully synthetic cannabinoids.

Tobacco Giant Philip Morris Sells Medical Device Business, Keeps Consumer Health Footprint

 
• By 

Philip Morris described a scenario of being essentially blacklisted by the health care sector and its CDMO partners as it threw in the towel on its £1.1bn acquisition of UK inhalation specialist Vectura. It agreed to offload the firm at a fraction of the initial cost.

Dietary Supplements Category Ranks Second For Food Fraud In EU

 
• By 

Report from European Commission's Alert and Cooperation Network finds EU consumers are being deceived by companies marketing supplements making unauthorized health claims and containing unapproved ingredients. 

More from Ingredients & Safety

OTC Sildenafil Not Coming To Australia Any Time Soon

 
• By 

Australian government finds an insufficient body of new evidence to support Rx-to-OTC switch of erectile dysfunction drug sildenafil since it was last considered in 2020.

No Evidence To Support Probiotics For Gut Microbiota Recovery After Antibiotics

 
• By 

It is well established that antibiotics disrupt the human gut microbiome, but what is not so well established is the use of probiotics to restore it, find the authors of a recently published scientific literature review.

UK Finds Turmeric Supplements Pose Risk To Health

 
• By 

UK food toxicity committee says substantial exceedances of the Acceptable Daily Intake of turmeric - such as through excessive supplement use - represents a potential health risk to humans.